

Press release for immediate release

## **Genomtec submits Prospectus to the Polish Financial Supervision Authority**

**Wroclaw, Poland - October 29, 2021. - Genomtec S.A. [WSE:GMT], a NewConnect-listed medical technology company developing a breakthrough Point of Care (POC) diagnostic system, Genomtec® ID, today filed with the Polish Financial Supervision Authority (KNF) a prospectus prepared in connection with the planned transfer of the Company's listing to the Warsaw Stock Exchange (WSE) main market. The Company's main motivation for the transfer is to increase its visibility and gain access to a larger group of long-term investors, including foreign ones.**

*“The transfer of shares to the main market will be another step in the implementation of our long-term strategy. The Company is growing steadily, our key product, Genomtec®ID is in the final stages of development, so we felt it was the right time to change the trading floor. We believe that Genomtec is a valuable company and the transfer of shares will increase our recognition not only among the largest institutional investors in Poland, but will also open the door to foreign investors. We want to build a stable shareholder structure, because MedTech projects are long-term and stability will facilitate our work on commercializing new solutions for patients and the healthcare system” - comments Miron Tokarski, CEO and co-founder of Genomtec.*

The Company's flagship solution Genomtec®ID - a mobile platform for genetic diagnostics - is entering the final stage of development. According to the presented schedule, Genomtec®ID will enter the phase of comparative testing and clinical evaluation of its devices at the turn of the year.

The Company's next major corporate event will take place on November 8, 2021, when the Company will release and report its Q3 2021 results. During the online conference call, the Company will discuss the next steps in the process of transferring to the main market of the WSE as well as the schedule of commercialisation of Genomtec®ID.

An invitation to the above-mentioned event will be sent out next week.

**#####**

### **Additional information available at:**

Genomtec S.A.  
Magdalena Kicińska  
+48 604 201 230  
[m.kicinska@genomtec.com](mailto:m.kicinska@genomtec.com)

### **About Genomtec S.A.**

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid



laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. Genomtec SA is headquartered in Wrocław.

More information at: [www.genomtec.com](http://www.genomtec.com)